SYNTHETIC PEPTIDE-BASED DNA COMPLEXES FOR NONVIRAL GENE DELIVERY

Citation
Lc. Smith et al., SYNTHETIC PEPTIDE-BASED DNA COMPLEXES FOR NONVIRAL GENE DELIVERY, Advanced drug delivery reviews, 30(1-3), 1998, pp. 115-131
Citations number
87
Categorie Soggetti
Pharmacology & Pharmacy
ISSN journal
0169409X
Volume
30
Issue
1-3
Year of publication
1998
Pages
115 - 131
Database
ISI
SICI code
0169-409X(1998)30:1-3<115:SPDCFN>2.0.ZU;2-B
Abstract
A major advantage of synthetic peptide-based DNA delivery systems is i ts flexibility. By design, the composition of the final complex can be easily modified in response to experimental results in vitro and in v ivo to take advantage of specific peptide sequences to overcome extra- and intracellular barriers to gene delivery. The extreme heterogeneit y which greatly complicates both the kinetics of DNA-poly(L-lysine) in teraction and the thermodynamic stability of the final DNA complexes i s avoided. Other unique features include the absence of biohazards rel ated to the viral genome as well as the production of the viral vector and the absence of limitations on the size of the therapeutic genes t hat can be inserted in the recombinant viral vector. In principle, if the gene can be cloned into an expression plasmid, it can be delivered as a synthetic DNA complex. Since these synthetic delivery systems ar e composed of small peptides which may be poorly antigenic, they hold the promise of repeated gene administration, a highly desirable featur e which will be important for gene targeting in vivo to endothelial ce lls, monocytes, hepatocytes and tumor cells. (C) 1998 Elsevier Science B.V.